$PACS

Murray Jason Hulse sold $10.4M of PACS

Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 236,116 shares of PACS Group, Inc. (PACS) at an average of $44.20 ($43.34–$44.85, $10.44M total) across 5 trades over 2026-08-17 to 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Murray Jason Hulse
Published Aug 20, 2026, 12:32 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PACS
Bearish
high confidence
Mentioned
$PACS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSBearishMed
01

Why it matters

The disclosed sale represents the first public report of a large insider divestiture for PACS.

02

Market read

Large insider sell may prompt short‑term price pressure and influence sentiment in the medical‑device niche.

03

What to watch

The 10b5-1 plan may have been set before any material news, and the sale does not coincide with any operational issues.

Relevance 6/10Novelty 7/10Timing: filed 2026-08-19 after market close

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$PACSBearishHigh confidence
Context

CEO Murray Hulse sold 236,116 shares for $10.4M via a 10b5-1 plan, reducing his stake to 54.8M shares.

Expected impact

Potential short-term pressure on PACS stock as market digests the large insider sale.

Evidence & confidence

A $10M sale by a top insider often signals reduced confidence and can trigger sell‑offs, especially given the high ownership level.

Market effects

May raise concerns for the medical device sector about insider confidence.

Limited to US markets where PACS trades.

Low, as PACS is a small‑cap US company.

Counterpoint

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • Murray Jason Hulse

    Co‑Founder, CEO & Chairman of PACS Group, Inc.

  • PACS Group, Inc.

    US‑listed medical device company (ticker PACS).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACSHighAI 8/10

Why is PACS stock rallying today?

PACS stock rose 3.3% premarket after announcing two growth initiatives: acquiring 32 Florida nursing facilities and closing 11 more from the Eduro Healthcare deal, expanding its network to 355 buildings. The company's stock has recovered from a 52-week low of $7.50, now trading at $43.52. PACS's low leverage and favorable Medicare reimbursements support its growth strategy.

$PACSMed

PACS Group stock rises on Florida expansion, Eduro closings

PACS Group (NYSE:PACS) shares rose 3.3% premarket after announcing plans to acquire 32 Florida skilled nursing facilities, adding 4,049 beds. The deal, expected to close Q4, expands PACS's southern footprint. Additionally, PACS completed closings on 11 more Eduro Healthcare facilities, bringing total Eduro closings to 31 of 34. The company now operates 355 facilities across 7 states. CEO Jason Murray highlighted Florida's growth potential.

$PACSHigh

PACS Group, Inc. (PACS): Results of Operations and Financial Condition

PACS Group, Inc. (PACS) filed an SEC Form 8-K — Results of Operations and Financial Condition. PACS Group, Inc. Reports Second Quarter 2026 Results Conference Call and Webcast Scheduled for Tomorrow, August 5, 2026, at 11:30 am ET. SALT LAKE CITY, Utah, August 4, 2026 – PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of

$PACSMedAI 8/10

Shearwater Group Contract Extension Worth £25m Lifts AIM Shares 17.6%

Shearwater Group said it secured a five-year £25m contract extension with a UK telecoms client, covering packet monitoring and forensic services. £12.5m is to be recognised in 2025-26, but cash is expected after year end; net cash is forecast at £5.6m and pre-tax profit at £1.1m. Shares rose 17.6% to 43.5p. Polar Capital and Supreme also moved on results.